Allianz Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
Other funds holding SPRY
Allianz Asset Management's SPRY Position: Q3 2026 in Review
Allianz Asset Management sold out of ARS Pharmaceuticals (SPRY) in Q3 2026, closing a stake of 10,200 shares — an estimated $81.7K sold.
Allianz Asset Management first reported a position in SPRY in Q2 2025 and held it in 3 quarters. The position peaked at $639K in Q2 2025. 190 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.
- Allianz Asset Management reported no remaining ARS Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
- Allianz Asset Management sold 10,200 ARS Pharmaceuticals shares in Q3 2026, an estimated $81.7K.
- Allianz Asset Management first reported a position in ARS Pharmaceuticals in Q2 2025 and held it in 3 quarters.
- Allianz Asset Management's ARS Pharmaceuticals position peaked at $639K in Q2 2025.
- 190 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.
Based on Allianz Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.